PainReform Ltd. (PRFX)
NASDAQ: PRFX · Real-Time Price · USD
3.100
-0.050 (-1.59%)
At close: Mar 3, 2025, 4:00 PM
3.000
-0.100 (-3.23%)
Pre-market: Mar 4, 2025, 7:37 AM EST
PainReform Employees
PainReform had 7 employees as of December 31, 2023. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change (1Y)
1
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$2,524,714
Market Cap
2.71M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 7 | 1 | 16.67% |
| Dec 31, 2022 | 6 | 2 | 50.00% |
| Dec 31, 2021 | 4 | -6 | -60.00% |
| Dec 31, 2020 | 10 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
PRFX News
- 13 days ago - PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity - GlobeNewsWire
- 2 months ago - PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110 - GlobeNewsWire
- 3 months ago - PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial - GlobeNewsWire
- 4 months ago - PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement - GlobeNewsWire
- 6 months ago - PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110 - GlobeNewsWire
- 6 months ago - PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds - GlobeNewsWire
- 7 months ago - PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study - GlobeNewsWire
- 7 months ago - PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses - GlobeNewsWire